Added
Updated
Q/C Technologies
MyMD is a clinical-stage pharma company developing therapeutic platforms for autoimmune diseases and aging, and a novel CBD derivative.
Founded
2014MyMD is a clinical-stage pharma company developing therapeutic platforms for autoimmune diseases and aging, and a novel CBD derivative.
Founded with a mission to extend healthy lifespan, MyMD Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing innovative therapeutic platforms. The company focuses on two primary products: MYMD-1, a small molecule drug platform targeting autoimmune diseases and aging by regulating the immunometabolic system, and SUPERA-CBD, a novel CBD derivative aimed at chronic pain, anxiety, and other conditions. MyMD aims to revolutionize treatments for age-related diseases and autoimmune disorders, positioning itself in the biotech and pharmaceutical markets.
Notable affiliated individuals include key scientists and industry experts who have contributed to the development of MyMD's groundbreaking therapies. The company has garnered attention through its merger with Akers Biosciences, which has been featured in multiple media outlets. Key achievements include advancing MYMD-1 through clinical stages and developing SUPERA-CBD as a promising therapeutic candidate. MyMD Pharmaceuticals is making a significant impact by addressing unmet medical needs and improving the quality of life for patients with chronic diseases.
Companies similar to Q/C Technologies include D&D Pharmatech, MycoMedica Life Sciences, Pure Green Pharmaceuticals and Kadmus Pharmaceuticals.
Q/C Technologies was founded in 2014.
Q/C Technologies' headquarters is located in Baltimore, MD, US.
Q/C Technologies' most recent funding round was for $15M (USD) in February 2023.
As of Feb 21, 2023, Q/C Technologies has raised a total of $15M (USD).
Q/C Technologies has 9 employees as of Feb 6, 2024.
Pure Green Pharmaceuticals
pgpharma.co
